Cancer drug may help flush HIV from hiding spots; 'chemo brain' could offer clues on long Covid's brain fog

New, early-stage research suggests the cancer drug Keytruda could also help flush latent HIV from the hidden reservoirs where it lurks. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Early research suggests cancer drug could help flush HIV from its hiding spots By Angus Chen NIAID/NIH New, early-stage research suggests the cancer drug Keytruda could also help flush latent HIV from the hidden reservoirs where it lurks. Read More In 'chemo brain,' researchers see clues to unravel long Covid's brain fog By Elizabeth Cooney Stanford The comparison offers new insight into an often debilitating symptom that up to a third of people with long Covid experience. Read More Patchwork system for rationing a Covid drug sends immunocompromised patients on a 'Hunger Games hunt' By Eric Boodman Molly Ferguson for STAT The patchwork system for distributing the Covid drug Evusheld creates a crazed, time-zone-spanning scramble for patients. Read More Sponsor content by STAT Events STAT Event: How biomarkers are changing cancer care The way doctors treat cancer is evolving. On Feb. 2, STAT looks into this by examining how advances in technology are changing the way biomarkers are used. Register here to join the conversation. STAT+: Illumina's embrace of long-read technology signals a shift in the DNA-sequencing market By Jonathan Wosen Adobe Long-read technology is an approach that could help diagnose rare diseases and decipher parts of the human genome that remain a mystery. Read More STAT+: Will the Biden administration approach march-in rights like Trump? Fight over pricey cancer drug offers a test By Ed Silverman Adobe “The fact that NIH is even contemplating march-in is significant," said Robert Cook-Deegan, a professor at Arizona State University. Read More STAT+: Future of Gilead blood cancer drug is clouded after studies are stopped due to safety issue By Adam Feuerstein Yichuan Cao/Sipa USA With the future of magrolimab now in doubt, pressure builds on Gilead to maximize the potential of its other cancer-focused acquisitions. Read More Tuesday, February 1, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser